Business
GB Sciences Initiates Cannabis-based Therapy Clinical Trials Consulting Services Agreement with Worldwide Clinical Trials, Inc.
GB Sciences Initiates Cannabis-based Therapy Clinical Trials Consulting Services Agreement with Worldwide Clinical Trials, Inc..
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nGB Sciences Initiates Cannabis-based Therapy Clinical Trials Consulting Services Agreement with Worldwide Clinical Trials, Inc.\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nGB Sciences Initiates Cannabis-based Therapy Clinical Trials Consulting Services Agreement with Worldwide Clinical Trials, Inc.\nPR Newswire\nLAS VEGAS, July 17, 2017\n\n\n\nLAS VEGAS, July 17, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) has signed a Consulting Services Agreement with Worldwide Clinical Trials, Inc. to evaluate the company's intellectual property portfolio and to assist with pre-IND planning for its proprietary cannabis-based formulations. These pre-IND consulting services will be performed by the Chief Medical and Scientific Officer (CMSO) of Worldwide, Michael F. Murphy, MD, PhD, as the representative of an extended Worldwide team. Dr. Murphy has participated in the IND application process for multiple small molecules and biologics with 19 therapeutic targets, across five divisions of the FDA. Dr. Murphy was also the Clinical Research and Excellence (CARE) Lifetime Achievement Award recipient for 2017. The award is presented annually to an extraordinary individual with exceptional contributions and a consistent history of service to the clinical research industry throughout their career.\n\n\nAccording to Dr. Murphy, \"Current research and development practices emphasize the importance of coordinated activity by industry, academia, and contract research organizations in the evaluation of innovative products, like those of GB Sciences. The process enhances program efficiency, facilitates the integration of the perspective of diverse stakeholders early in clinical development, and is a testament to GB Sciences' strategic vision for the development of their portfolio of products. Worldwide is very pleased to be a contributor to that process, and the state-of-the-art technology which it reflects.\" \n\nGrowblox Life Sciences LLC, a wholly owned subsidiary of GB Sciences, Inc., has filed three provisional patent applications to protect complex mixtures derived from th...